Journal
ACS SUSTAINABLE CHEMISTRY & ENGINEERING
Volume 7, Issue 1, Pages 1038-1051Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acssuschemeng.8b04673
Keywords
Continuous pharmaceutical manufacturing; Biocatalysis; Techno-economic analysis; Environment; Surrogate-based optimization
Categories
Funding
- MOE AcRF Grant in Singapore [R-279-000-513-133, R-279-000-541-114]
Ask authors/readers for more resources
This work proposes a comprehensive framework of biocatalytic continuous manufacturing of sitagliptin, the active pharmaceutical ingredient of the leading dipeptidyl peptidase-4 inhibitor antidiabetic drug. Continuous manufacturing has the advantages of quality consistency, reduced waste generation, and cost-effectiveness in comparison to batch processes. Furthermore, compared to traditional catalysts, biocatalysts have lighter environmental footprints. An end-to-end continuous manufacturing process is designed and the reaction kinetics of the biocatalytic reaction is determined according to the published data. Based on the steady-state model of a plug-flow microreactor, the optimal productivity is determined to be 2.6 x 10(-2)mol h(-1) using surrogate-based optimization. In addition, an assessment of the process' environmental impacts demonstrates its sustainability with a lower E-factor of 53 compared to 200 of traditional processes. A comprehensive techno-economic analysis has also been performed, validating the economic feasibility of this process with a net present value of $150 million over a 20 year time period. Therefore, this present work demonstrates the feasibility, sustainability, and economic competitiveness of the proposed process.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available